<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00210119</url>
  </required_header>
  <id_info>
    <org_study_id>IB2005-25</org_study_id>
    <secondary_id>AFR22</secondary_id>
    <nct_id>NCT00210119</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response</brief_title>
  <acronym>AFR22</acronym>
  <official_title>Multicentric Phase II Study to Evaluate Feasibility and Efficacy of Association of Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response After One Year of Imatinib Mesylate Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <brief_summary>
    <textblock>
      Imatinib mesylate is standard treatment of Chronic myeloid leukaemia, complete cytogenetic&#xD;
      response is obtained in most of cases but molecular response concerned only a small part of&#xD;
      the patients. To increase molecular response ratio we decided to increase imatinib dose to&#xD;
      limited resistance to this drug and to add zoledronate for it anti tumoral activity to&#xD;
      increase anti leukemic effect. We plan to accrue 37 patients in 5 centers. We will analyse&#xD;
      molecular expression of BCR-ABL transcript after 6 months of treatment, safety, duration of&#xD;
      response, VEGF expression and LTgd production.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">July 12, 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Molecular Response</measure>
    <time_frame>6 months</time_frame>
    <description>A patient is considered to be in molecular response if at least one of the following conditions is observed :&#xD;
- a complete molecular response at 6 months defined by PCR negativation tested on twice&#xD;
OR&#xD;
- reduction of BCR-ABL transcript level &gt; 2 Log from the start of from initiation of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Reduction of BCR-ABL Transcript Level &gt; 4.5 Log From the Start of From Initiation of Treatment</measure>
    <time_frame>6 months</time_frame>
    <description>reduction of BCR-ABL transcript level &gt; 4.5 Log from the start of from initiation of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Myeloid Leukemia, Chronic</condition>
  <arm_group>
    <arm_group_label>Imatinib mesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib mesylate 600 or 800 mg/day PO + zoledronate 4 mg IV over 15 min every 3 weeks for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glivec</intervention_name>
    <arm_group_label>Imatinib mesylate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria: at registration· Chronic myeloid leukaemia Ph+ confirmed by&#xD;
             cytogenetic analysis or BCR-ABL translocation by molecular biology· Chronic&#xD;
             phase:-&lt;15% blast cells in blood and 5% in bone marrow-&lt;30% blast cells+promyelocyte&#xD;
             cells in blood and bone marrow-&lt;20% basophils in blood-&gt;100.000 platelets· Without&#xD;
             extra medullar attempt excepted hepatosplenomagalia· First line of treatment· Biology&#xD;
             and biochemistry with normal levels· Male or female&gt;18 years old· Signed written&#xD;
             consent· ECOG&lt;3At inclusion· Chronic myeloid leukaemia with cytogenetic response&#xD;
             without molecular response after one year of treatment by imatinib and BCR-ABL&#xD;
             transcript detected by RT-PCR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  · Other cancer excepted basocellular or cervix carcinoma · Major surgery in last 2&#xD;
             weeks previous inclusion· Women who are pregnant or breastfeeding (are unable to use&#xD;
             an acceptable method to avoid pregnancy of his partner for the entire study period)·&#xD;
             Dementia or altered mental status that would prohibit the understanding or rendering&#xD;
             of informed consent · Abnormal renal function with creatinine clearance &lt; 30 ml/&#xD;
             minuteAccording to Cockcroft-Gault : CrCl= [[140-age (years)] x weight (kg)]/ [72 x&#xD;
             serum creatinine (mg/dL)] {x 0.85 for women}· Chronic myeloid leukaemia in acute phase&#xD;
             or in pass to be in acute phase · Treatment with bisphosphonates in last 6 months&#xD;
             previous inclusion · Intolerance to bisphosphonates: hypersensitivity, on course&#xD;
             dental problem, including tooth or mandibular infection; dental traumatism or recent&#xD;
             diagnosis or previous mandibular osteonecrosis, or dental extraction with&#xD;
             cicatrisation delay or necessity to set bone evidence · Mandibular surgery in last 6&#xD;
             weeks or planned in the future during treatment (tooth extraction)· Serious&#xD;
             uncontrolled medical disorder or active infection that would impair the ability of the&#xD;
             subject to receive protocol therapy: diabetes, thyroid pathology, neuropsychiatric&#xD;
             illness, myocardial infarction or congestive heart failure grade 3-4 according to &quot;&#xD;
             New York Heart association&quot;· History of psychiatric or depressive pathology · HIV&#xD;
             positivity known · Inclusion in other study investigating antineoplastic molecule in&#xD;
             last 30 days previous inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josy REIFFERS, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>September 29, 2021</results_first_submitted>
  <results_first_submitted_qc>September 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 28, 2021</results_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <keyword>Chronic myeloid leukemia</keyword>
  <keyword>imatinib mesylate</keyword>
  <keyword>zoledronate</keyword>
  <keyword>molecular response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The AFR-22 trial was based on a two-stage Simon's design, which included 17 patients in the first stage, followed by an additional 20 patients. Analysis of the first 17 evaluable patients showed insufficient efficacy of the study treatment. In accordance with the principle of Simon's two-stage design, enrollment was stopped.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Imatinib Mesylate</title>
          <description>Imatinib mesylate 600 or 800 mg/day PO + zoledronate 4 mg IV over 15 min every 3 weeks for 6 months.&#xD;
Glivec</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Imatinib Mesylate</title>
          <description>Imatinib mesylate 600 or 800 mg/day PO + zoledronate 4 mg IV over 15 min every 3 weeks for 6 months.&#xD;
Glivec</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.4" lower_limit="32.7" upper_limit="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Molecular Response</title>
        <description>A patient is considered to be in molecular response if at least one of the following conditions is observed :&#xD;
- a complete molecular response at 6 months defined by PCR negativation tested on twice&#xD;
OR&#xD;
- reduction of BCR-ABL transcript level &gt; 2 Log from the start of from initiation of treatment</description>
        <time_frame>6 months</time_frame>
        <population>2 patients were not assessable for the primary outcome measure : 1 not eligible and 1 not treated because of withdrawal</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Imatinib mesylate 600 or 800 mg/day PO + zoledronate 4 mg IV over 15 min every 3 weeks for 6 months.&#xD;
Glivec</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Molecular Response</title>
          <description>A patient is considered to be in molecular response if at least one of the following conditions is observed :&#xD;
- a complete molecular response at 6 months defined by PCR negativation tested on twice&#xD;
OR&#xD;
- reduction of BCR-ABL transcript level &gt; 2 Log from the start of from initiation of treatment</description>
          <population>2 patients were not assessable for the primary outcome measure : 1 not eligible and 1 not treated because of withdrawal</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Reduction of BCR-ABL Transcript Level &gt; 4.5 Log From the Start of From Initiation of Treatment</title>
        <description>reduction of BCR-ABL transcript level &gt; 4.5 Log from the start of from initiation of treatment</description>
        <time_frame>6 months</time_frame>
        <population>2 patients were not assessable for secondary outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Imatinib mesylate 600 or 800 mg/day PO + zoledronate 4 mg IV over 15 min every 3 weeks for 6 months.&#xD;
Glivec</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Reduction of BCR-ABL Transcript Level &gt; 4.5 Log From the Start of From Initiation of Treatment</title>
          <description>reduction of BCR-ABL transcript level &gt; 4.5 Log from the start of from initiation of treatment</description>
          <population>2 patients were not assessable for secondary outcome measures</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Only serious adverse events were monitored. Adverse events (non-serious) were not assessed/monitored during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Imatinib Mesylate</title>
          <description>Imatinib mesylate 600 or 800 mg/day PO + zoledronate 4 mg IV over 15 min every 3 weeks for 6 months.&#xD;
Glivec</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE V5.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <description>Acute pulmonary edema</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Gabriel Etienne</name_or_title>
      <organization>Institut Bergonie</organization>
      <email>g.etienne@bordeaux.unicancer.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

